Barclays raised the firm’s price target on CVS Health (CVS) to $93 from $87 and keeps an Overweight rating on the shares following the investor day. The company guided to mid-teens earnings growth through 2028, which includes margin improvement at Aetna and Care Delivery, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health price target raised to $97 from $96 at UBS
- CVS Health: Strong Financial Outlook and Strategic Initiatives Drive Buy Rating
- CVS Health’s Promising Growth Trajectory and Strategic Focus Drive Buy Rating
- CVS Health: Strategic Initiatives and Financial Outlook Drive Buy Rating
- CVS Health: Projected Growth and Strategic Capital Deployment Drive Buy Rating